Pasritamig is being evaluated with or without JNJ-9401 in the ongoing phase 3 KLK2-comPAS trial.
|Videos|December 13, 2022
Dr. Hafron highlights the most significant prostate cancer treatment advances in 2022
Author(s)Urology Times staff
Advertisement
In this interview, Jason M. Hafron, MD, recaps the biggest advances in the prostate cancer treatment paradigm in 2022. Hafron is a partner at the Michigan Institute of Urology, PC; an associate professor of Urology at the William Beaumont School of Medicine, Oakland University; and the director of Robotic Surgery at Beaumont Hospital Royal Oak in Michigan.
Advertisement
Related to this article
These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.
Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Biomarkers including HRR mutations, PTEN loss, and PSMA expression can guide triplet selection in mHSPC, according to Benjamin Garmezy, MD.
Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
2
Q&A: Suzanne B. Merrill, MD, FACS, on perioperative therapy in MIBC
3
Pasritamig combination yields 73% PSA response rate in phase 1 mCRPC study
4
SureCore needle: Interim data show longer, less fragmented cores
5